Clinical Trial Update: Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of lapatinib plus weekly paclitaxel for advanced urothelial cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Cancer

Drugs mentioned

• Lapatinib (Lapatinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Urothelial Cancer, Bladder Cancer | Phase 2 | Status: WITHDRAWN